Amgen stock after-hours at EUR 358.20: minus 1.12 percent versus Lang & Schwarz prior close
Published on 10/02/2026 at 19:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock was at EUR 358.20 after-hours at 7:32 p.m. CEST on October 2, 2026, down 1.12 percent versus the EUR 362.25 prior close at Lang & Schwarz.
Trading day in Germany
The move compares with the previous Lang & Schwarz closing price of EUR 362.25 from October 1, 2026. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Amgen stock.
Phase 3 study reaches primary endpoint
In a September 22, 2026 release, Amgen said its Phase 3 OASIZ 301 study of dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity met its primary endpoint. The company reported statistically significant and clinically meaningful improvement at Week 48, measured by the EULAR Sjögren's Syndrome Disease Activity Index, with improvements observed as early as Week 4 and sustained through Week 48.
Amgen said the most common adverse events were generally mild to moderate, while discontinuations due to adverse events were low and balanced across treatment groups. The company expects its Phase 3 OASIZ 303 study to complete in the fourth quarter of 2026.
